Pentagastrin-induced release of free fatty acids in healthy volunteers and patients with panic disorder: Effect of pretreatment with ethinyl estradiol

Journal of Psychiatry and Neuroscience

Volumn 28, Issue 2, 2003, Pages 127-133

  Morrow, Jarret D ^a   McManus, Karen ^a   Tait, Glendon R ^a   Bellavance, François ^b   Chrapko, Wendy ^a   Lara, Nathalie ^a   Le Mellédo, Jean Michel ^a,c  

^a UNIVERSITY OF ALBERTA   (Canada)

^b HEC MONTRÉAL   (Canada)

^c UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Cholesterol; Ethinyl estradiol; Fatty acids; Nonesterified; Panic disorder; Pentagastrin

Indexed keywords

ETHINYLESTRADIOL; FATTY ACID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PENTAGASTRIN; PLACEBO;

ADULT; ARTICLE; ATTENUATION; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; CROSSOVER PROCEDURE; DISEASE ASSOCIATION; DISEASE SEVERITY; DOSE TIME EFFECT RELATION; DOUBLE BLIND PROCEDURE; FATTY ACID METABOLISM; FREQUENCY ANALYSIS; HUMAN; HYPOTHESIS; LIPOLYSIS; MALE; PANIC; RANDOMIZED CONTROLLED TRIAL; STATISTICAL SIGNIFICANCE; STRESS; SYMPTOMATOLOGY; TIME; TREATMENT OUTCOME;

ADULT; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; ESTRADIOL CONGENERS; ETHINYL ESTRADIOL; FATTY ACIDS, NONESTERIFIED; GASTROINTESTINAL AGENTS; HUMANS; MALE; MIDDLE AGED; PENTAGASTRIN; TIME FACTORS;

EID: 0038693502     PISSN: 11804882     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (50)

1. Rozanski A, Blumenthal JA, Kaplan J. Impact of psychological factors on the pathogenesis of cardiovascular disease and the implications for therapy. Cardiology 1999;99:2192-217.
2. Kawachi I, Sparrow D, Vokonas PS, Weiss ST. Symptoms of anxiety and risk of coronary heart disease: the Normative Aging Study. Circulation 1994;90:2225-9.
3. Fleet RP, Beitman BD. Cardiovascular death from panic disorder and panic-like anxiety: a critical review of the literature. J Psychosorn Res 1998;44(1):71-80.
4. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Washington (DC): The Association; 1994.
5. Coryell W, Noyes R, Clancy J. Excess mortality in panic disorder: a comparison with primary unipolar depression. Arch Gen Psychiatry 1982;39:701-3.
6. Coryell W, Noyes R, House JD. Mortality among outpatients with anxiety disorders. Am J Psychiatry 1986;143(4):508-10.
7. Weissman MM, Markowitz JS, Oulette R, Greenwald S, Kahn JP. Panic disorder and cardiovascular/cerebrovascular problems: results from a community survey. Am J Psychiatry 1990;147:1504-8.
8. Haines AP, Imeson JD, Meade TW. Phobic anxiety and ischaemic heart disease. Br Med J (Clin Res Ed) 1987;295:297-9.
9. Stamler J, Daviglus ML, Garside DB, Dyer AR, Greenland P, Neaton JD. Relationship of baseline serum cholesterol levels in 3 large cohorts of younger men to long-term coronary, cardiovascular, and all-cause mortality and to longevity. JAMA 2000;284(3):365-7.
10. Bajwa WK, Asnis GM, Sanderson WC, Irfan A, Van Praag HM. High cholesterol levels in patients with panic disorder. Am J Psychiatry 1992;149:376-8.
11. Hayward C, Taylor CB, Roth WT, King R, Agras WS. Plasma lipid levels in patients with panic disorder or agoraphobia. Am J Psychiatry 1989;146:917-9.
12. Yamada K, Tsutsumi T, Fujii AI. Serum cholesterol levels in patients with panic disorders: a comparison with major depression and schizophrenia. Psychiatry Clin Neurosci 1997;51:31-4.
13. Shioiri T, Fujii K, Someya T, Takahashi S. Effect of pharmacotherapy on serum cholesterol levels in patients with panic disorder. Acta Pscychiatr Scand 1996;93:164-7.
14. Agargun MY, Kara H, Algun E, Sekeroglu R, Tarakcioglu M. High cholesterol levels in patients with sleep panic. Biol Psychiatry 1996;40:1064-5.
15. Tancer ME, Stein MB, Moul DE, Uhde TU. Normal serum cholesterol in panic disorder. Biol Psychiatry 1990;27:99-101.
16. Lacerda ALT, Caetano D, Caetano SC. Cholesterol levels in panic disorder, generalized anxiety disorder and major depression. Arq Neuropsiquiatr 2000;58(2-B):408-11.
17. McCann BS, Carter J, Vaughan M, Raskind M, Wilkinson CW, Veith RC. Cardiovascular and neuroendocrine responses to extended laboratory challenge. Psychosom Med 1993;55(6):497-504.
18. McCann BS, Magee MS, Brolyes FC, Vaughan M, Albers JJ, Knopp RH. Acute psychological stress and epinephrine infusion in normolipidemic and hyperlipidemic men: effects on plasma lipid and apoprotein concentrations. Psychosom Med 1995;57:165-76.
19. Muldoon MF, Bachen EA, Manuck SB, Waldstein SR, Bricker PL, Bennett JA. Acute cholesterol responses to mental stress and change in posture. Arch Intern Med 1992,152:775-80.
20. Muldoon MF, Herbert TB, Patterson SM, Kameneva M, Raible R, Manuck SB. Effects of acute psychological stress on serum lipid levels, hemoconcentration, and blood viscosity. Arch Intern Med 1995;155:615-20.
21. Patterson SM, Gottdiener JS, Hecht G, Vargot S, Krant DS. Effects of acute mental stress on serum lipids: mediating effects of plasma volume. Pschosom Med 1993;55:525-32.
22. Patterson SM, Mattews KA, Allen MT, Owens JF. Stress-induced hemoconcentration of blood cells and lipids in healthy women during acute psychological stress. Health Psychol 1995;14:319-24.
23. Del Rio G, Velardo A, Zizzo G, Avogaro A, Cipolli C, Della Casa L, et al. Effect of estradiol on the sympathathoadrenal response to mental stress in normal men. J Clin Endocrinol Metab 1994;79(3):836-40.
24. Lewis GF. Fatty acid regulation of very low density lipoprotein production [review]. Curr Opin Lipidol 1997;8(3):146-53.
25. Corvilain B. Lipoprotein metabolism [review]. Rev Med Brux 1997;18(1):3-9.
26. Kang S, Davis RA. Cholesterol and hepatic lipoprotein assembly and secretion [review]. Biochim Biophys Acta 2000;1529(1-3): 223-30.
27. Steiner G, Poapst ME, Shumak SL, Foster DM. Metabolism of apolipoprotein B-containing lipoproteins. Methods Enzymol 1986;129:395-440.
28. Bradwejn J, Koszycki D, Shriqui C. Enhanced sensitivity to cholecystokinin tetrapeptide in panic disorder. Clinical and behavioral findings. Arch Gen Psychiatry 1991;48:603-10.
29. Abelson JL, Nesse RM. Pentagastrin infusions in patients with panic disorder. I. Symptoms and cardiovascular responses. Biol Psychiatry 1994;36:73-83.
30. Le Mellédo JM, Bradwejn J, Koszycki D, Bichet DG, Bellavance F. The role of the β-adrenergic system in CCK-4 induced panic symptoms. Biol Psychiatry 1998;44:363-6.
31. Barrett-Connor E. Sex differences in coronary disease: Why are women so superior? The 1995 Ancel Keys lecture. Circulation 1997;95:252-64.
32. Hulley S, Grady D, Bust T, Furberg C, Herrington D, Riggs B, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA 1998;280(7):605-13.
33. Stampfer MJ, Colditz GA. Estrogen replacement therapy and coronary heart disease: a quantitative assessment of the epidemiologic evidence. Prev Med 1991;20:47-63.
34. Stampfer MJ, Willett WC, Colditz GA, Rosner B, Speizer FE, Hennekens CH. A prospective study of post-menopausal estrogen therapy and coronary heart disease. N Engl J Med 1985;313:1044-9.
35. Grodstein F, Stampfer MJ, Manson JE, Colditz GA, Willett WC, Rosner B, et al. Postmenopausal estrogen and progestin use and the risk of cardiovascular disease. N Engl J Med 1996;335(7):453-61.
36. Henderson BE, Paginini-Hill A, Ross RK. Decreased mortality in users of estrogen replacement therapy. Arch Intern Med 1991;151:75-8.
37. Mercuro G, Pitzalis L, Podda A, Zoncu S, Pilia I, Melis GB, et al. Effects of acute administration of natural progesterone on peripheral vascular responsiveness in healthy postmenopausal women. Am J Cardiol 1999;84:214-8.
38. Tait GR, McManus K, Bellavance F, Lara N, Chrapko W, Le Mellédo JM. Neuroactive steroid changes in response to challenge with the panicogenic agent pentagastrin. Psychoneuroendocrinology 2002;27(4):417-29.
39. Katerndahl DA, Realini JP. Comorbid psychiatric disorders in subjects with panic attacks. J Nerv Ment Dis 1997;185:669-74.
40. Kaplan HI, Sadock BJ. Kaplan and Sadock's synopsis of psychiatry: behavioral sciences, clinical psychiatry. 8th ed. Baltimore: Williams and Wilkins; 1998. p. 594.
41. Jones B, Kenward MG. Design and analysis of crossover trials. New York: Chapman and Hall; 1989.
42. Van Megen HJGM, Westenberg HGM, denBoer JA, Haigh JRM, Traub M. Pentagastrin induced panic attacks: enhanced sensitivity in panic disorder patients. Psychopharmacology 1994;114:449-55.
43. McManus K, Tait G, Bellavance F, Le Mellédo J. Effect of ethinyl estradiol on the panic response to the panicogenic agent pentagastrin. J Affect Disord 2001;66(2-3):273-9.
44. Deci PA, Lydiard B, Santos AB, Arana GW. Oral contraceptive and panic disorder. J Clin Psychiatry 1992;53:163-5.
45. Korhonen S, Saarijarvi S, Aito M. Estradiol treatment of panic disorder in a fertile-aged woman. Hum Psychopharmacol 1995;10:485-6.
46. Price WA, Heil D. Estrogen-induced panic attacks. Psychosom Med 1988;29:433-5.
47. Usiroyama T, Okamoto Y, Toyoda K, Sugimoto O. A case of panic disorder induced by oral contraceptives. Acta Obstet Gynecol Scand 1992;71:78-80.
48. La Rovere MT, Bigger JT Jr, Marcus FI, Mortara A, Schwartz PJ. Baroreflex sensitivity and heart-rate variability in prediction of total cardiac mortality after myocardial infarction. ATRAMI (Autonomic Tone and Reflexes After Myocardial Infarction) Investigators. Lancet 1998;351(9101):478-84.
49. Paolisso G, Manzella D, Rizzo M, Ragno E, Barbieri M, Varricchio G, et al. Elevated plasma fatty acid concentrations stimulate the cardiac autonomic nervous system in healthy subjects. Am J Clin Nutr 2000;72(3):723-30.
50. Yeragani VK, Pohl R, Berger R, Balon R, Ramesh C, Glitz D, et al. Decreased heart rate variability in panic disorder patients: a study of power-spectral analysis of heart rate. Psychiatr Res 1993;46(1):89-103.